Carboxyethyl aminobutyric acid (CEGABA) lacks cytotoxicity and genotoxicity and stimulates cell proliferation and migration in vitro
- 18 Downloads
Cosmeceuticals are cosmetics formulated using compounds with medical-like benefits. Though the antiaging effect of carboxyethyl aminobutyric acid (CEGABA) has been discussed, its action mechanism in cosmeceuticals remains unclear. This study assessed the in vitro efficacy and safety of CEGABA. NHI-3T3 mouse fibroblast cell line was treated with two CEGABA concentrations (50 and 500 μmol/L) for 24 h, 48 h, and 72 h. Cytotoxicity and genotoxicity were evaluated by colorimetry (MTT) and the alkaline version of the comet assay, respectively. Flow cytometry and the scratch-wound assay were used to assess cell-cycle phase distributions and cell migration rates. Compared with the untreated control, CEGABA increased cell growth 1.6 times after 72 h, independent of dose. The compound also decreased cell replication time by 4 h. These findings seem to be related with the approximately 1.5-times increase in phase S cells numbers. Importantly, in vitro wound healing improved roughly 20% after treatment with CEGABA for 24 h and persisted after 48 h, indicating culture recovery. The time-dependent proliferation and migration of fibroblasts induced by CEGABA besides the fact that the compound is neither genotoxic nor cytotoxic makes it an ideal candidate in the development of cosmeceuticals in antiaging therapy.
KeywordsCEGABA Cytotoxicity Fibroblasts Genotoxicity Scratch-wound assay
This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-Brasil (CAPES) (Grant no. 181/2012). Finance Code 001.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.An JJ, Eum WS, Kwon HS, Koh JS, Lee SY, Baek JH, Cho YJ, Kim DW, Han KH, Park J, Jang SH, Choi SY (2013) Protective effects of skin permeable epidermal and fibroblast growth factor against ultraviolet-induced skin damage and human skin wrinkles. J Cosmet Dermatol 12:287–295. https://doi.org/10.1111/jocd.12067 CrossRefGoogle Scholar
- 6.Davis SC, Perez R (2009) Cosmeceuticals and natural products: wound healing. Clin Dermatol 27:502–506. https://doi.org/10.1016/j.clindermatol.2009.05.015 CrossRefGoogle Scholar
- 10.Gomes RK, Damazio MG (2009) Cosmetologia: descomplicando os princípios ativos, 3rd edn. Livraria Médica Paulista, São PauloGoogle Scholar
- 13.International Standard ISO 10993-5-ISO/EN10993-5 (2009) Biological evaluation of medical devices, part 5: tests for cytotoxicity in vitro methods, 3rd edn. ISO, GenevaGoogle Scholar
- 18.Minois N, Carmona-Gutierrez D, Madeo F (2011) Polyamines in aging and disease. Aging (Albany NY) 3:716–732. http://doi.org/10.18632/aging.100361
- 28.Oricha BS (2010) Cosmeceuticals: a review. Afr J Pharm Pharmacol 4:127–129Google Scholar
- 30.Savoldi F, Ceroni M, Fussi F, Curti M (1987) Pharmacological effects of CEGABA, a new aminoacid occurring in mammalian brain. Farmaco Sci 42:77–79Google Scholar
- 34.Souza VM, Antunes D (2009) Ativos dermatológicos, 3rd edn. Pharmabooks, São PauloGoogle Scholar
- 39.Verschoore M, Nielson M (2017) The rationale of anti-aging cosmetic ingredients. J Drugs Dermatol 16:s94–s97Google Scholar
- 40.Vockel M, Pollok S, Breitenbach U, Ridderbusch I, Kreienkamp H, Brandner JM (2011) Somatostatin inhibits cell migration and reduces cell counts of human keratinocytes and delays epidermal wound healing in an ex vivo wound model. PLoS One 6:e19740. https://doi.org/10.1371/journal.pone.0019740 CrossRefGoogle Scholar